Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Schizophrenia: full-pipeline trial registry
76 of 318 indexed Schizophrenia trials are currently recruiting.
Corpus placement: #23 of 28,707 conditions by registered trial count.
318 US clinical trials · 76 currently recruiting · #23 of 28,707 conditions by registered trial count
Schizophrenia: 318 US clinical trials tracked, 76 recruiting.
Schizophrenia is the subject of 318 registered US clinical trials on ClinicalTrials.gov, 76 of them currently open to new participants. 90 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is University of Maryland, Baltimore, running 14 of these trials.
Enrollment posture brief
Registry condition schizophrenia
OPEN 76 | RECR 24% | LATE 90 | EARLY 87 | RANK #23 | SPON 14
Volume-matched condition peers
Nearest open-share peer: Dehydration (24% recruiting · 21 trials)
Schizophrenia lists 76 open slots (24% of 318 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Schizophrenia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Schizophrenia is recruiting below its size-band peers.
76 of 318 indexed trials (23.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Schizophrenia trials is spread across many organizations.
University of Maryland, Baltimore accounts for 14 of 318 trials (4.4%). 129 distinct sponsors appear on at least one study for this condition label.
-
Typical Schizophrenia enrolment sits around 83 participants.
Median target enrolment is 83 among the 316 trials that report a genuine target (sentinel values excluded). 169 of those (53.5%) plan for fewer than 100 participants.
-
Schizophrenia research is mostly interventional.
290 interventional and 28 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
318 total, page 5 of 7
Development of a Mobile Heath Augmented Brief Suicide Prevention Intervention for People With SMI
University of California, San Diego
NCT03198364
Social Cognitive Training for Psychosis: Treatment Development
Yale University
NCT01579422
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
Veterans Medical Research Foundation
NCT00338949
Cognitive - Behavioral Therapy
US Department of Veterans Affairs
NCT00018629
Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine
Delwyn D. Miller
NCT00581932
Treatment of Mania Symptoms With Drug Therapy
Palo Alto Veterans Institute for Research
NCT00183443
Metabolic Signatures and Biomarkers in Schizophrenia
Duke University
NCT00466310
Cognitive Training for Patients With Schizophrenia
University of California, San Diego
NCT01521026
Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
Indivior
NCT03978832
A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia
Massachusetts General Hospital
NCT00538070
Improving Accessibility and Personalization of CR for Schizophrenia
New York State Psychiatric Institute
NCT03576976
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
Braeburn Pharmaceuticals
NCT02658357
Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia
Sheppard Pratt Health System
NCT01242371
Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
Duke University
NCT00215579
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
University of California, San Diego
NCT04857983
A System for Preference Assessment in Mental Health
University of California, Los Angeles
NCT02183844
Web-Based Weight Management for Individuals With Mental Illness
University of California, Los Angeles
NCT01324973
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
Indiana University
NCT01339858
High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
Manhattan Psychiatric Center
NCT00297947
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization
NCT05848700
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
Massachusetts General Hospital
NCT01082588
Aripiprazole Oral Acceptability Trial
Otsuka Pharmaceutical Development & Commercialization
NCT00101569
The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics
AstraZeneca
NCT00986531
In-person vs. Remote Wellness Support
The University of Texas Health Science Center at San Antonio
NCT04526067
Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness
VA Office of Research and Development
NCT01244854
Benefits of Physical Exercise in Schizophrenia
VA Office of Research and Development
NCT02716584
A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia
Click Therapeutics
NCT06136936
Study to Demonstrate Cognitive Enhancing Effects of BF2.649
University of Texas Southwestern Medical Center
NCT00690274
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine
University of California, Los Angeles
NCT02505477
Development of a Mobile System for Self-management of Schizophrenia (SOS)
Dartmouth-Hitchcock Medical Center
NCT01969500
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
University of Massachusetts, Worcester
NCT03526354
Do Self-Report and Physician Impressions of Adherence to Oral Antipsychotic Medication Agree With Objective Data?
The University of Texas Health Science Center at San Antonio
NCT00223522
Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations
Yale University
NCT00042159
Omega-3 Dietary Supplements in Schizophrenia
Delbert Robinson
NCT01786239
Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness
University of Washington
NCT03062267
Exploratory Study of a Digital Therapeutics in People With Schizophrenia
Click Therapeutics
NCT05438160
Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode
University of California, Los Angeles
NCT02267070
A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
Luye Pharma Group
NCT03751488
Levetiracetam in Early Psychosis
NYU Langone Health
NCT03129360
Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia
H. Lundbeck A/S
NCT02202213
Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia
Beth Israel Deaconess Medical Center
NCT03648268
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
Alkermes
NCT02636842
Folate Supplementation in Schizophrenia
Massachusetts General Hospital
NCT00249288
Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
Nathan Kline Institute for Psychiatric Research
NCT00287820
D-serine Augmentation of Neuroplasticity
New York State Psychiatric Institute
NCT03711500
Single Ascending Dose Study of RBP-7000
Indivior
NCT02768649
Antipsychotics and Blood Vessel Function
Jess G. Fiedorowicz
NCT00585273
Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without Schizophrenia
University of Maryland, Baltimore
NCT00770237
PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia
Indivior
NCT02687984
Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
University of Maryland, Baltimore
NCT00176436
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 40 |
| Phase 3 | 50 |
| Phase 4 | 40 |
Top Sponsors
Named interventions
Most-linked intervention names on Schizophrenia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Schizophrenia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Schizophrenia page
318 registered trials, 76 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 76 Schizophrenia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Maryland, Baltimore sponsors the most Schizophrenia trials on record, review their full trial history before evaluating a specific study. See University of Maryland, Baltimore's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Schizophrenia condition card totals 318 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.